Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

panobinostat nanoparticle formulation MTX110

A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity
Code name:MTX 110
MTX-110
MTX110
Search NCI's Drug Dictionary